Since inflammation in the tumour microenvironment is commonly modulated to benefit the tumour [31], and the observed complement activation was not due to apoptosis of EGFR inhibited cells, we hypothesize that cancer cells may modulate complement activation during growth inhibitory conditions. The gene discussed is EGFR; the disease is neoplasm.